Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression

Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model

(2018) Kentaro Miyake et al.   CELL CYCLE

AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas

(2015) Caitlin D. May et al.   BMC CANCER

Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis

(2015) Amanda Kirane et al.   CANCER RESEARCH

Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome

(2015) Katia Rea et al.   Oncotarget

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)

(2015) Daruka Mahadevan et al.   Oncotarget

Recurrent epimutation of SDHC in gastrointestinal stromal tumors

(2014) J. K. Killian et al.   Science Translational Medicine

Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction

(2012) Margherita Nannini et al.   Future Oncology

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

AXL regulates mesothelioma proliferation and invasiveness

(2010) W-B Ou et al.   ONCOGENE

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors

(2008) W-b Ou et al.   ONCOGENE